The Medsintez plant from Novouralsk (the Sverdlovsk region, a part of the Yunona Holding), which is only four years old, was awarded the title of Laureate of the Russian Government's Prize in the field of quality.

According to the Sverdlovsk region's Government Department, this is the highest national prize awarded not only for a particular product's quality but also for immutable guarantees of this quality - the best management system and business process organization, which allow the company to comprehensively improve its business. There are very few winners of this quality award, so they are widely renowned, recognized in the global community and have significant market advantages. The Medsintez plant passed three most difficult qualifying rounds of the 2007 competition at first try and way ahead of other applicants to become, for the first time in the modern Russia history, the laureate as a representative of the pharmaceutical industry.

Remember that, on April 11, 2008, the Medsintez plant from Novouralsk, which is supervised by the governor, received a license for insulin production, and Eduard Rossel immediately informed of the fact the elected president Dmitry Medvedev. According to Viktor Koksharov, Chairman of the Government of the Sverdlovsk region, the appearance of insulin under the Medsintez brand is a convincing example of a successful public-private partnership. The Chairman believes that this step will be followed by the development and implementation of the regional target program on dialysis. In particular, 11 dialysis centres built by the Yunona holding are to appear in the Middle Urals in the years to come.

According to GMP experts, Kate McCormick, Head of the pharmaceutical directorate of Heathside Information Services Ltd (Great Britain), gave the Ural plant, which was the first in Russia to organize the large-scale insulin production compliant with international standards, the highest rating too. In her letter to Eduard Rossel, the Governor of the Sverdlovsk region, she pointed out that the company implemented high-tech production of GEHI (genetically engineered human insulin) that meets not only national standards but also more stringent requirements of the European Union, which makes the products competitive at the international level.

It should be noted that the director of the foreign company has visited the Novouralsk plant twice; the last time was in June this year. In her letter, she also, on behalf of the EU GMP experts, thanked the Governor of the Sverdlovsk region for helping harmonize pharmaceutical production levels of Russia and Europe.